INTRODUCTION {#S5}
============

Obesity is a major health concern in the US: more than one-third of US adults (34.9% or 78.6 million) are obese ([@R1]). Obese individuals have significantly increased risks of developing many diseases, including cardiovascular diseases, hypertension, type II diabetes, and certain types of cancer ([@R2]). The annual medical care cost to treat obesity and obesity-assocaited diseases is estimated to be around \$190 billion in the US ([@R3]). Therefore, it is of critical importance to better understand the mechanism by which obesity increases the risks of various human diseases, which could facilitate the development of effective therapeutic strategies.

The enzymatic metabolism of polyunsaturated fatty acids (PUFAs), such as arachidonic acid (ARA, 20:4ω-6), leads to formation of bioactive lipid metabolites (LMs), which are important lipid signaling molecules involved in regulation of many fundamental physiological and pathological processes ([@R4], [@R5], [@R6]) (see a simplified scheme in [Fig. S1a](#SD1){ref-type="supplementary-material"}, the abbreviations of LMs are in [Table S1](#SD1){ref-type="supplementary-material"}). There are three major pathways involved in enzymatic metabolism of PUFAs: cyclooxygenase (COX-1 and COX-2), lipoxygenase (5-LOX, and 12/15-LOX), and cytochrome P450 (CYP). The COX pathway leads to formation of prostaglandins, which are important mediators to induce inflammation and pain; and COX-2 is the therapeutic target of many anti-inflammatory drugs on the market ([@R4]). The LOX pathway produces leukotrienes and hydroxyl fatty acids, which are predominately pro-inflammatory and play critical roles in inflammatory diseases such as asthma ([@R4]). The CYP pathway converts PUFAs to fatty acid epoxides, which have a variety of beneficial effects such as anti-inflammatory, cardio-protective, vasodilative, and analgesic actions ([@R5], [@R6]). Besides ARA, other PUFAs, including linoleic acid (LA, 18:2ω-6), α-linolenic acid (α-LA, 18:3ω-3), γ-linolenic acid (γ-LA, 18:3ω-6), dihomo-γ-linolenic acid (DGLA, 20:3ω-6), eicosapentaenoic acid (EPA, 20:5ω-3), and docosahexaenoic acid (DHA, 22:6ω-3), are also efficient alternative substrates of these enzymes and are converted to the corresponding LMs with unique biological activities ([@R6], [@R7], [@R8]) ([Fig. S1b--f](#SD1){ref-type="supplementary-material"}). Together, this leads to formation of a large array of LMs with diverse chemical structures, many of which have potent biological activities.

Previous research has shown that LMs play critical roles in pathology of obesity. In obese Zucker rats, there is attenuated production of prostacyclin (PGI~2~), which is a LM produced by COX enzymes with potent anti-inflammatory and vasodilative effects ([@R9]). Reduced levels of this beneficial LM could contribute to increased adipose inflammation and impaired adipose tissue blood flow (ATBF) in obesity. Dietary feeding of high-fat diet (HFD) increased tissue levels of LOX-derived leukotriene B~4~ (LTB~4~); and inhibition of LTB~4~ receptor protected mice from HFD-induced insulin resistance and hepatic steatosis ([@R10]), suggesting that LOX pathway contributes to increased risks of obesity-associated diseases. Dietary feeding of HFD also reduced levels of CYP-derived epoxyeicosatrienoic acids (EETs), which have potent anti-inflammatory, vasodilative, and cardio-protective effects ([@R11], [@R12], [@R13]). Pharmacological inhibition or transgenic deletion of soluble epoxide hydrolase (sEH, the dominant enzyme in degrading EETs) have been shown to protect mice from various adverse effects induced by obesity ([@R14], [@R15], [@R16], [@R17], [@R18], [@R19], [@R20], [@R21]). Together, these results support that LMs play critical roles in regulating the pathology of obesity.

Most previous studies of LMs in obesity have only studied single or limited number of LMs ([@R9], [@R10], [@R14], [@R15], [@R16], [@R17], [@R18], [@R19], [@R20], [@R21]). However, the enzymatic metabolism of PUFAs produces hundreds of LMs, which could have different or even opposite biological activities, it would be difficult to understand the biological processes by only studying single or limited number of LMs ([@R22]). Therefore, it is important to conduct comprehensive profiling of a variety of LMs in tissues, which could help us to better understand their roles in pathology of obesity, in order to develop novel biomarkers or therapeutic targets for obesity and obesity-associated diseases. To this end, here we used a LC-MS/MS-based lipidomics approach, which can simultaneously measure the concentrations of \> 100 LMs produced by COX (COX-1, COX-2), LOX (5-LOX, 12/15-LOX) and CYP enzymes from ARA, LA, α-LA, DGLA, EPA, and DHA ([@R23], [@R24]) (see [Table S1](#SD1){ref-type="supplementary-material"}), to systematically analyze how lipid signaling is deregulated in obesity.

MATERIALS AND METHODS {#S6}
=====================

Obesity experiment {#S7}
------------------

The animal experiment was conducted in accordance with the protocols approved by the Institutional Animal Care and Use Committee of UMass-Amherst. C57BL/6 male mice (6-week age) were maintained on a high-fat diet (60% kcal% fat, purchased from Research Diet Inc., catalog number D12492) and a control diet (10 kcal% fat, D12450J from Research Diet Inc.) for 8 weeks. Diet information can be found at <http://www.researchdiets.com/opensourcediets/stock-diets/dio-series-diets>.

LC-MS/MS-based lipidomics analysis {#S8}
----------------------------------

To extract lipid metabolites from adipose tissues, \~100 mg tissues were mixed with an antioxidant solution (0.2 mg/mL butylated hydroxytoluene and 0.2 mg/mL triphenylphosphine in methanol), 10 µL of deuterated internal standards (500 nM of d~4~-6-keto PGF1a, d~4~-TXB~2~, d~4~-PGE~2~, d~4~-LTB~4~, d~11~-14,15-DHET, d~4~-9-HODE, d~8~-5-HETE, d~11~-11,12-EET), and 400 µL extract solution (0.1% acetic acid with 0.2 mg/mL butylated hydroxytoluene in methanol), and then homogenized; the resulting homogenates were kept in −80 °C overnight. After centrifugation of the homogenates, the pellets were washed with methanol (containing 0.1% butylated hydroxytoluene and 0.1% acetic acid) and then combined with the supernatant. The lipid metabolites in the combined solutions were loaded onto pre-washed Waters^®^ Oasis solid phase extraction (SPE) cartridges, washed with 95:5 v/v water/methanol with 0.1% acetic acid, the analytes were eluted with methanol and ethyl acetate, dried using a centrifugal vacuum evaporator, then reconstituted in methanol for LC-MS/MS analysis. The LC-MS/MS analysis was carried out on an Agilent 1200SL HPLC system (Agilent, Santa Clara, CA) coupled to a 4000 QTRAP MS/MS (AB Sciex, Foster City, CA) as described in our previous report ([@R24]). The lipid mediators whose levels were above the detection limit of LC-MS/MS were reported.

Real-time PCR (RT-PCR) analysis {#S9}
-------------------------------

Total RNA was isolated from gonadal adipose tissues using TRIzol Reagent (Life technologies, Carlsbad, CA) according to manufacturer's instruction. Conversion of up to 2 µg of total RNA to single stranded cDNA was preformed using High-Capacity cDNA Reverse Transcription Kit (Life technologies, Carlsbad, CA) according to manufacturer's instruction. Quantitative RT-PCR was conducted using Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fisher Scientific, Agawam, MA) on a DNA Engine Opticon^®^ 2 System (Bio-Rad Laboratories, Hercules, CA) with specific mouse primers. The primers used in this research were: *Cyp2j5* (sense) 5'-TCTGGGAAGCACTCCATCTCA-3' and (antisense) 5'-CCCTGGTGGGTAGTTTTTGG-3', *Cyp2j6* (sense) 5'-TTAGCCACGATCTGGGCAG-3' and (antisense) 5'-CTGGGGGATAGTTCTTGGGG-3', *Cyp2c44* (sense) 5'-GCTGCCCTATACAGATGCCG-3' and (antisense) 5'-GTGACGCTAAGAGTTGCCCA-3', *Ephx2* (sense) 5'-GCGTTCGACCTTGACGGAG-3' and (antisense) 5'-TGTAGCTTTCATCCATGAGTGGT-3', *Alox15* (sense) 5'-GGCTCCAACAACGAGGTCTAC-3' and (antisense) 5'-AGGTATTCTGACACATCCACCTT-3', *Alox5* (sense) 5'-ACTACATCTACCTCAGCCTCATT-3' and (antisense) 5'-GGTGACATCGTAGGAGTCCAC-3', *Cox2* (sense) 5'- TTCAACACACTCTATCACTGGC-3' and (antisense) 5'-AGAAGCGTTTGCGGTACTCAT-3', *Pla2* (sense) 5'-TGCCTTTCCTGTAGGCTGTTC-3' and (antisense) 5'-CGCAGGTCTCGTAGCATCTG-3', *Ptges* (sense) 5'-GGATGCGCTGAAACGTGGA-3' and (antisense) 5'-CAGGAATGAGTACACGAAGCC-3', *Ptgis* (sense) 5'-ACAGCATCAAACAATTTGTCGTC-3' and (antisense) 5'-GCATCAGACCGAAGCCATATCT-3', *Pla2g4a* (sense) 5'-CAGCACATTATAGTGGAACACCA-3' and (antisense) 5'-AGTGTCCAGCATATCGCCAAA-3', *Pla2g12a* (sense) 5'-TGCCTTTCCTGTAGGCTGTTC-3' and (antisense) 5'-CGCAGGTCTCGTAGCATCTG-3'. The results of target genes were normalized to *β-actin* gene and expressed to the control group mice using the 2^−ΔΔCt^ method. The primer to analyze *β-actin* is (sense) 5'-GGCTGTATTCCCCTCCATCG-3' and (antisense) 5'-CCAGTTGGTAACAATGCCATGT-3'.

Fatty acid composition analysis {#S10}
-------------------------------

Total lipids from gonadal adipose tissue were extracted as previously described ([@R25]), then treated with 3 N methanolic HCl at 55°C for 40 minutes to prepare the fatty acid methyl esters (FAMEs) ([@R26]). The resulted FAMEs dissolved in hexane were used for GC-MS analysis, using Shimadzu GC-MS-QP2010 SE (Tokyo, Japan). Oven conditions: initial temperature 50°C; temperature increase: 20°C/min to 200 °C, then increase 2°C/min to 220°C and held for 142.5 minutes. Other conditions: injector temperature 250 °C; detector temperature 250 °C; carrier gas helium, split ratio: 10:1. Column: Supelcowax 10 (fused silica), 100 m × 0.25 mm × 0.25 Pm. The FAMEs were identified by comparing with the standards (Sigma-Aldrich, St. Louis, MO, or Nu-Chek Prep, Elysian, MN) or by their mass spectra, which were further compared to the NIST Mass Spectral library.

Data Analysis {#S11}
-------------

All data are expressed as the mean ± standard error of the mean (SEM). For the comparison between the control group and HFD group, Shapiro-Wilk test was used to verify the normality of data. When data were normally distributed, statistical significance was determined using two-side t-test; otherwise, significance was determined by Mann-Whitney U test. All of these data analysis was performed by using SigmaPlot software (San Jose, CA). The principal component analysis (PCA) was implemented using MetaboAnalyst (<http://www.metaboanalyst.ca/>). The data were scaled using auto scaling before the analysis. P values less than 0.05 are reported as statistically significant.

RESULTS {#S12}
=======

CYP-derived LMs in adipose tissues {#S13}
----------------------------------

After 8 weeks of dietary feeding, HFD significantly increased body weight and adipose tissue weight in C57BL/6 mice ([Fig. S2](#SD1){ref-type="supplementary-material"}). These results are consistent with previous studies of HFD on obesity ([@R27]). We used LC-MS/MS-based lipidomics to compare the profiles of LMs in inguinal, gonadal, and interscapular adipose tissues of mice fed on HFD or control diet. Among the three major PUFA metabolizing pathways (COX, LOX, and CYP), CYP-derived fatty acid epoxides are the most dramatically altered LMs in adipose tissues ([Fig. 1](#F1){ref-type="fig"} and [Fig. S3](#SD1){ref-type="supplementary-material"}). PCA analysis of the lipidomics data shows the difference between HFD group from control group, and fatty acid epoxides were the most important lipid mediators contributing to the differentiation ([Fig. S3](#SD1){ref-type="supplementary-material"}). The levels of fatty acid epoxides derived from several PUFAs, including epoxyoctadecenoic acids (EpOMEs) derived from LA, EETs from ARA, epoxydocosapentaenoic acids (EpDPEs) from DHA, and epoxyoctadecadienoic acids (EpODEs) from α-LA, were significantly reduced in different adipose tissues (inguinal, gonadal, and interscapular fats) of HFD-fed mice ([Fig. 2a--c](#F2){ref-type="fig"}). For example, the concentrations of 11,12-EET and 14,15-EET were reduced by respective 88±20% and 89±18% in inguinal adipose tissues (P ≤ 0.001), and were reduced by respective 88±13% and 89±11% in gonadal fat tissues of HFD-fed mice (P ≤ 0.001) ([Fig. 2a--b](#F2){ref-type="fig"}). The ratios of fatty acid epoxides to the corresponding diols were also reduced in the tissues of HFD-fed mice ([Fig. S4](#SD1){ref-type="supplementary-material"}). There is no difference in terms of recovery of deuterated LM standards between control and HFD group (see [Fig. S5](#SD1){ref-type="supplementary-material"}).

The fatty acid epoxides are further metabolized by soluble epoxide hydrolase (sEH) to generate the corresponding fatty acid diols ([@R10]). Consistent with reduced adipose levels of fatty acid epoxides, the levels of fatty acid diols were also significantly reduced ([Fig. 2a--c](#F2){ref-type="fig"}). For example, the levels of 11,12-dihydroxyeicosatrienoic acid (11,12\--DHET), which is a sEH metabolite of 11,12-EET, were reduced by 54.5±10.7% (mean ± SEM) in gonadal adipose tissues of HFD-fed mice (P ≤ 0.001) ([Fig. 2b](#F2){ref-type="fig"}). We need to point out in the adipose tissues, the concentrations of fatty acid epoxides were much higher than those of the corresponding fatty acid diols. For example, the concentration of 11,12-EET was \~73-fold higher than its sEH metabolite 11,12-DHET in gonadal adipose tissues of control mice ([Fig. 2b](#F2){ref-type="fig"}).

We further analyzed whether there is a correlation of adipose tissue weight with adipose concentration of CYP-derived LMs. In gonadal fat tissues, the adipose tissue weight inversely correlated with adipose concentration of fatty acid epoxides such as 11,12-EET and 19,20-EpDPE ([Fig. 2d](#F2){ref-type="fig"}), supporting a critical role of these fatty acid epoxides in obesity.

COX-derived LMs in adipose tissues {#S14}
----------------------------------

The metabolism of PUFAs by COX enzymes lead to formation of prostaglandin H~2~ (PGH~2~), which was further enzymatically metabolized to generate various prostaglandins ([Fig. 3a](#F3){ref-type="fig"}). Compared with CYP-derived LMs, the profiles of COX-derived LMs showed more complicated patterns. In inguinal adipose tissues, the levels of COX-derived LMs were not changed ([Fig. 3b](#F3){ref-type="fig"}), suggesting that COX pathway is not likely to be involved in the biology of inguinal adipose tissues. In gonadal adipose tissues, the concentrations of PGI~2~ (as measured by its stable metabolite 6-keto-PGF~1a~) and PGE~2~ were significantly reduced in HFD-fed mice ([Fig. 3c](#F3){ref-type="fig"}). In interscapular adipose tissues, the concentrations of PGF~2α~ and PGE~2~ were significantly reduced in HFD-fed mice (P \< 0.05, [Fig. 3d](#F3){ref-type="fig"}).

5-LOX-derived LMs in adipose tissues {#S15}
------------------------------------

The metabolism of ARA by 5-LOX leads to formation of 5-hydroperoxyeicosatetraenoic acid (5-HpETE), which is then converted to at least two classes of LMs: (1) 5-hydroxyeicosatetraenoic acid (5-HETE), or similar LMs such as α-LA-derived 9-HOTrE and EPA-derived 5-HEPE, and (2) LTB~4~, or similar LMs such as EPA-derived leukotriene B~5~ (LTB~5~) ([Fig. 4a](#F4){ref-type="fig"}). Dietary feeding of HFD reduced levels of 5-HETE-series LMs (such as 5-HETE, 9-HOTrE, and 5-HEPE), while increased levels of LTB~4~ in adipose tissues ([Fig. 4b--d](#F4){ref-type="fig"}). The tissue levels of LTB~4~ were significantly increased in inguinal, gonadal, and interscapular adipose tissues of HFD-fed mice ([Fig. 4b--d](#F4){ref-type="fig"}), which is in agreement with recent studies which showed that HFD increased tissue levels of LTB~4~ ([@R10]).

12/15-LOX-derived LMs in adipose tissues {#S16}
----------------------------------------

The metabolism of PUFAs by 12/15-LOX leads to formation of a series of LMs ([Fig. 5a](#F5){ref-type="fig"}). LC-MS/MS showed that many of these LMs were reduced in adipose tissues of HFD-fed mice ([Fig. 5b--d](#F5){ref-type="fig"}). For example, the tissue levels of 15-HETE were significantly reduced in inguinal, gonadal, and interscapular adipose tissues of HFD-fed mice ([Fig. 5b--d](#F5){ref-type="fig"}). 12-HETE, which is among the most abundant LOX-derived LMs in adipose tissues, was reduced by 71.7±6.78% (mean ± SEM) in interscapular adipose tissue of HFD-fed mice ([Fig. 5d](#F5){ref-type="fig"}).

Fatty acid composition and expression of COX, LOX and CYP in adipose tissues {#S17}
----------------------------------------------------------------------------

The tissue profiles of LMs are in part mediated by fatty acid composition and expression of PUFA metabolizing enzymes in the tissues ([@R6]). To understand the mechanisms by which HFD modulated LMs in adipose tissues, we analyzed fatty acid composition and gene expression of COX, LOX and CYP in adipose tissues. We focused on gonadal adipose tissues, which are the largest adipose tissues, since we have observed significant changes of most LMs in gonadal fat ([Fig. 1](#F1){ref-type="fig"}--[@R5]).

For fatty acid composition, as expected, triglycerides were major lipids in the gonadal adipose tissue, with minimum amount of phospholipids (determined by TLC method based on Ref ([@R28]), data not shown), which is consistent to previous studies ([@R29]). Therefore, we analyzed fatty acid composition from the total lipid of adipose tissues. GC-MS analysis showed that dietary feeding of HFD did not change the tissue levels of ARA and α-LA, and slightly increased tissue levels of LA (22.50±0.18% in HFD group *vs.* 17.78±0.44% in control group, P \< 0.001) ([Table. S2](#SD1){ref-type="supplementary-material"}). These results support that dietary feeding of HFD did not reduce levels of PUFAs in adipose tissues, suggesting that the reduced levels of many LMs in adipose tissues were not due to lack of PUFA substrates.

For gene expressions of PUFA metabolizing enzymes, RT-PCR showed that the expressions of several CYP epoxygenases, such as *Cyp2j5, Cyp2j6*, and *Cyp2c44*, were significantly reduced in the gonadal adipose tissues of HFD-fed mice ([Fig. 6a](#F6){ref-type="fig"}), which is well consistent with the reduced levels of CYP-derived fatty acid epoxides in adipose tissues (see [Fig. 2b](#F2){ref-type="fig"}). The expression of *Ephx2* (encoding sEH) was not changed ([Fig. 6a](#F6){ref-type="fig"}). For COX pathway, the gene expression of *Cox2* was not changed, while the expressions of *Ptges* (encoding microsomal prostaglandin E synthase) and *Ptgis* (encoding PGI~2~ synthase) were significantly reduced in HFD-fed mice ([Fig. 6b](#F6){ref-type="fig"}). This is consistent with the LC-MS/MS analysis which showed that only PGE~2~ and PGI~2~, but not other COX-derived LMs, were reduced in adipose tissues of HFD-fed mice ([Fig. 3c](#F3){ref-type="fig"}). For LOX pathways, the gene expressions of *Alox15* (encoding 12/15-LOX) and *Alox5* (encoding 5-LOX) were not significantly changed ([Fig. 6c](#F6){ref-type="fig"}), suggesting that the effects of HFD on LOX-derived LMs may be though modulations of down-stream enzymes. Finally, we analyzed the expression of *Pla2* (including cytosolic calcium-dependent *Pla2g4a* and secretory *Pla2g12a* ([@R4])), and found little change of this gene ([Fig. 6c](#F6){ref-type="fig"}). Together, these results support that HFD changed tissue profiles of LMs mainly through modulation of the expressions of PUFA metabolizing enzymes in adipose tissues.

DISCUSSION {#S18}
==========

In this study, we conducted a LC-MS/MS-based lipidomics analysis of HFD-induced obesity in mice. Our central finding is that HFD significantly modulated the profiles of LMs in adipose tissues of mice. Among the three major PUFA metabolizing pathways (COX, LOX and CYP), CYP-derived fatty acid epoxides are the most dramatically changed LMs in adipose tissues of HFD-induced obesity. Almost all types of fatty acid epoxides, including EpOMEs derived from LA, EETs from ARA, EpDPEs from DHA, and EpODEs from α-LA, were reduced by 70--90% in different types of adipose tissues. Based on our GC-MS analysis of fatty acid composition and RT-PCR analysis of PUFA metabolizing enzymes, these changes were most likely caused by reduced expressions of CYP epoxygenases, not because the PUFA substrates were reduced in adipose tissues of HFD-fed mice. The ratios of fatty acid epoxides to the corresponding diols were reduced in the tissues of HFD-fed mice, while the gene expression of *Ephx2* (encoding sEH) was not changed. This may be because the fatty acid diols could be further metabolized, such as by phase II enzymes through conjugations of the hydroxyl groups, leading to removal of fatty acid diols ([@R6]). Our results are consistent with previous studies, which showed that EETs are reduced in adipose tissues of HFD-fed mice ([@R11]). Many of these fatty acid epoxides have beneficial effects on health. ARA-derived EETs have been shown to have potent anti-inflammatory, vasodilative, anti-hypertensive, cardio-protective, renal-protective, and analgesic actions ([@R30]). DHA-derived EpDPEs have been shown to be the most potent fatty acid epoxides in dilation of blood vessels, with EC~50~ values of 0.5--24 pM for dilation of porcine coronary arterioles ([@R31]). Our own study has shown that EDPs have potent anti-angiogenic, anti-cancer and anti-metastatic effects *in vitro* and *in vivo* ([@R32]). Therefore, reduced levels of these beneficial LMs, in particular EETs and EDPs, may contribute to the adverse effects of obesity. This is supported by recent studies, which showed that pharmacological inhibition or transgenic deletion of sEH, which is the dominant enzyme in degrading fatty acid epoxides, protected mice form various adverse consequences of obesity, such as endoplasmic reticulum stress, metabolic syndrome, hepatic steatosis, inflammation, and endothelial dysfunction ([@R11], [@R14], [@R15], [@R16], [@R17], [@R18], [@R19], [@R20], [@R21]). Together, these results strongly support that CYP-derived fatty acid epoxides play important roles in regulating pathology of obesity.

The profiles of COX- and LOX-derived LMs showed more complicated pattern in adipose tissues of HFD-induced obesity. For COX pathway, the relative balance of vasodilative PGI~2~ (as measured by its stable metabolite 6-keto-PGF~1a~) and vasoconstrictive TXA~2~ (as measured by its stable metabolite TXB~2~) plays critical role in regulating vascular tone and cardiovascular functions ([@R4], [@R33]). Our study showed that dietary feeding of HFD reduced adipose levels of vasodilative PGI~2~, while had little effect on vasoconstrictive TXA~2~. These results support that PGI~2~ pathway, but not TXA~2~ pathway, may contribute to some adverse effects of obesity. Our results are consistent with previous studies which showed that biosynthesis of PGI~2~, but not TXA~2~, was attenuated in obese Zucker rats ([@R9]). We also found that the tissue levels of PGE~2~ were significantly reduced in obese mice. This is consistent with previous studies of HFD on adipose tissue levels of PGE~2~ ([@R34], [@R35], [@R36], [@R37]). The biological significance of PGE~2~ remains to be determined. On one hand, PGE~2~ is a potent vasodilator, reduced level of PGE~2~ could contribute to reduced ATBF of obesity ([@R4]); on the other hand, PGE~2~ is a potent inducer of inflammation ([@R4]), reduced level of PGE~2~ is not consistent with the enhanced adipose inflammation in obesity. Previous studies have shown that HFD induced a dynamic change of adipose level of PGE~2~: in the early stage of HFD feeding (day 4 post HFD feeding), PGE~2~ was increased in adipose tissues; while at a later stage (day 14), its concentration was reduced in adipose tissues ([@R35]). These results support that there may be a highly time-dependent change of tissue levels of LMs, in order to respond to varied cellular stimulations at different stages of obesity development.

For LOX pathway, only the concentration of 5-LOX-derived LTB~4~ was significantly increased in adipose tissues. This is consistent with recent studies which showed that HFD increased tissue levels of LTB~4~; in addition, inhibition of LTB~4~ receptor protected mice from HFD-induced insulin resistance and hepatic steatosis ([@R10]), supporting a critical role of LTB~4~ in pathology of obesity. For 12/15-LOX pathway, our results showed that the many 12/15-LOX-derived LMs 12-HETE, 15-HETE, 15(s)-HETrE, and 13-HOTrE) were reduced in adipose tissues of HFD-fed mice. Our results are consistent with previous studies which showed that HFD reduced adipose concentrations of 12-HETE and 15-HETE ([@R37]). Some previous studies have shown that 12/15-LOX pathway is activated in obesity ([@R38]); and these different results could be because different animal models of obesity are used. Many of the LOX-derived hydroxyl fatty acids and leukotrienes have potent effects to regulate inflammation and vascular tone ([@R4]). It remains to determine whether reduced levels of 12/15-LOX-derived LMs contributed to adverse effects of obesity.

In conclusion, our lipidomics analysis showed that HFD significantly modulated the profiles of LMs in adipose tissues of mice. In particular, CYP-derived fatty acid epoxides are the most dramatically altered LMs in HFD-induced obesity, suggesting that these novel LMs could play critical roles in pathology of obesity. This lipidomics study lays the foundation to further investigate the functional roles of LMs in obesity, which could facilitate the development of novel biomarkers or therapeutic targets for obesity and obesity-associated diseases.
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![Cell plot demonstarets that CYP-derived fatty acid epoxides are the most dramatically altered LMs in adipose tissues of HFD-fed mice. (***a***) inguinal adipose tissues. (***b***) gonadal adipose tissues. (***c***) interscapular adipose tissues. n = 12 mice per group.](nihms821120f1){#F1}

![Dietary feeding of HFD reduces levels of CYP-derived fatty acid epoxides and fatty acid diols in adipose tissues. (***a***) profiles of CYP-derived LMs in inguinal adipose tissues. (***b***) profiles of CYP-derived LMs in gonadal adipose tissues. (***c***) profiles of CYP-derived LMs in interscapular adipose tissues. (**d**) correlations of tissue concentration of fatty acid epoxides and tissue weight in gonadal adipose tissues. n = 12 mice per group, the results are mean ± SEM, \* P \< 0.05, \*\* P ≤ 0.001.](nihms821120f2){#F2}

![Dietary feeding of HFD modulates COX-derived LMs in adipose tissues. (***a***) a simplified sheme of COX-2 pathway. Abbreviations: COX: cycloxygenase, PTGIS: prostacyclin synthase or PGI~2~ synthase, PTGES: prostaglandin E synthase, see abbreviations of LMs in supplemental inforamtion [Table S2](#SD1){ref-type="supplementary-material"}. (***b*)** profiles of COX-derived LMs in inguinal adipose tissues. (***c***) profiles of COX-derived LMs in gonadal adipose tissues. (***d***) profiles of COX-derived LMs in interscapular adipose tissues. n = 12 mice per group, the results are mean ± SEM, \* P \< 0.05.](nihms821120f3){#F3}

![Dietary feeding of HFD modulates 5-LOX-derived LMs in adipose tissues. (***a***) a simplified sheme of 5-LOX pathway. (***b***) profiles of 5-LOX-derived LMs in inguinal adipose tissues. (***c***) profiles of 5-LOX-derived LMs in gonadal adipose tissues. (***d***) profiles of 5-LOX-derived LMs in interscapular adipose tissues. n = 12 mice per group, the results are mean ± SEM, \* P \< 0.05, \*\* P ≤ 0.001.](nihms821120f4){#F4}

![Dietary feeding of HFD modulates 12/15-LOX-derived LMs in adipose tissues. (***a***) a simplified sheme of 12/15-LOX pathway. (***b***) profiles of 12/15-LOX-derived LMs in inguinal adipose tissues. (***c***) profiles of 12/15-LOX-derived LMs in gonadal adipose tissues. (***d***) profiles of 12/15-LOX-derived LMs in interscapular adipose tissues. n = 12 mice per group, the results are mean ± SEM, \* P \< 0.05, \*\* P ≤ 0.001.](nihms821120f5){#F5}

![Effect of HFD on gene expresions of PUFA metabolizing enzymes in gonadal adipose tissues. (***a***) gene expressions of enzymes involved in CYP pathway. (***b***) gene expressions of enzymes in COX pathway. (***c***) gene expressions of enzymes in LOX pathway, as well as phospholipase A~2~ (PLA~2~). n = 4--6 per group, the results are mean ± SEM, \* P \< 0.05, n.s. not significant.](nihms821120f6){#F6}

What is already known about this subject? {#S20}
=========================================

Obesity is correlated with deregulated profiles of lipid mediators in adipose tissues.

Most studies only studied single or limited number of lipid mediators.

Previous studies focused on cyclooxygenase- and lipoxygenase-derived lipid mediators.

What does this study add? {#S21}
=========================

We did a first lipidomics analysis of obesity in mice, which systematically analyzed \>100 lipid mediators.

The results showed that P450-derived epoxy fatty acids, which were unappreciated in previous studies, were the most dramatically changed lipid mediators in obesity.
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